Home › NDC Lookup › RxCUI directory › RxCUI 1092567

{7 (24 HR guanfacine 1 MG Extended Release Oral Tablet [Intuniv]) / 7 (24 HR guanfacine 2... — RxCUI 1092567

RxNorm drug concept · Brand name pack
RxCUI 1092567 Brand name pack · BPCK Retired or remapped concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1092567
Official name{7 (24 HR guanfacine 1 MG Extended Release Oral Tablet [Intuniv]) / 7 (24 HR guanfacine 2 MG Extended Release Oral Tablet [Intuniv]) } Pack [Intuniv Kit 7/7]
Concept typeBrand name pack (BPCK)
RxNorm statusRetired or remapped concept
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)3,725 prescriptions · 14 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web

No related-concept groups were available for this RxCUI in the loaded RxNorm data. That does not prove that no related concepts exist.

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 1092567 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
54092-0513-02 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (54092-513-02) Intuniv Takeda Pharmaceuticals America, Inc. 2009-09-02
54092-0515-02 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (54092-515-02) Intuniv Takeda Pharmaceuticals America, Inc. 2009-09-02
54092-0517-02 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (54092-517-02) Intuniv Takeda Pharmaceuticals America, Inc. 2009-09-02
54092-0519-02 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (54092-519-02) Intuniv Takeda Pharmaceuticals America, Inc. 2009-09-02
Observed labelers: Takeda Pharmaceuticals America, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.